The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...